AR035735A1 - Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamento - Google Patents
Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamentoInfo
- Publication number
- AR035735A1 AR035735A1 ARP020100196A ARP020100196A AR035735A1 AR 035735 A1 AR035735 A1 AR 035735A1 AR P020100196 A ARP020100196 A AR P020100196A AR P020100196 A ARP020100196 A AR P020100196A AR 035735 A1 AR035735 A1 AR 035735A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- pharmaceutical composition
- drug
- administered
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona una composición farmacéutica que se puede administrar por vía oral, que comprende un fármaco poco hidrosoluble, como por ejemplo un compuesto de pirazolilbencensulfonamida sustituida, de acción inhibidora selectiva de la COX-2, un líquido disolvente con por lo menos un disolvente farmacéuticamente aceptable, y un polímero reductor de la turbidez, en donde (a) una porción considerable del fármaco, por ejemplo por lo menos aproximadamente el 15% por peso, está disuelto o solubilizado en el líquido disolvente; y (b) el polímero está presente en una cantidad suficiente para inhibir considerablemente la cristalización y/o la precipitación del fármaco en el líquido gástrico simulado. El uso de dichas composiciones en el fabricación de medicamentos para el tratamiento de trastornos específicos mediados por la COX-2, también se describe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26255501P | 2001-01-18 | 2001-01-18 | |
US28460801P | 2001-04-17 | 2001-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035735A1 true AR035735A1 (es) | 2004-07-07 |
Family
ID=26949305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100196A AR035735A1 (es) | 2001-01-18 | 2002-01-18 | Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamento |
Country Status (18)
Country | Link |
---|---|
US (2) | US7115565B2 (es) |
EP (1) | EP1365812A2 (es) |
JP (1) | JP2004520359A (es) |
KR (1) | KR20030070118A (es) |
CN (1) | CN100335136C (es) |
AR (1) | AR035735A1 (es) |
BR (1) | BR0206580A (es) |
CA (1) | CA2434338A1 (es) |
CZ (1) | CZ20031844A3 (es) |
EA (1) | EA006383B1 (es) |
HK (1) | HK1065959A1 (es) |
IL (1) | IL156916A0 (es) |
MX (1) | MXPA03006357A (es) |
NO (1) | NO20033244L (es) |
NZ (1) | NZ526976A (es) |
PE (1) | PE20020799A1 (es) |
PL (1) | PL363215A1 (es) |
WO (1) | WO2002056878A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL367337A1 (en) * | 2001-05-31 | 2005-02-21 | Pharmacia Corporation | Skin-permeable selective cyclooxygenase-2 inhibitor composition |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
FR2838349B1 (fr) * | 2002-04-15 | 2004-06-25 | Laurence Paris | Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication |
CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
KR100533458B1 (ko) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | 파클리탁셀의 가용화용 조성물 및 그의 제조 방법 |
WO2004022032A2 (en) * | 2002-07-31 | 2004-03-18 | Pharmacia Corporation | Pharmaceutical dosage form comprising a sulfite compound |
CA2511881C (en) * | 2002-12-30 | 2013-06-25 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a sodium salt of celecoxib with improved dissolution |
EP2339328A3 (en) * | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
FR2854072B1 (fr) * | 2003-04-23 | 2006-08-04 | Centre Nat Rech Scient | Vecteur pour administration par voie orale |
US20060292186A1 (en) * | 2003-08-29 | 2006-12-28 | Novagali Pharma Sa | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
EP1510206A1 (en) * | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
US20050220866A1 (en) * | 2004-04-02 | 2005-10-06 | Dr. Reddy's Laboratories Limited | Novel capsule formulations of etoposide for oral use |
KR20050099311A (ko) * | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
PE20060416A1 (es) * | 2004-08-03 | 2006-06-09 | Novartis Ag | Composicion de inhibidores de renina e inhibidores de proteinas de efusion |
EP3165220B1 (en) | 2004-12-03 | 2019-04-03 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
JP2006265626A (ja) * | 2005-03-24 | 2006-10-05 | Dowa Mining Co Ltd | 銀回収方法 |
EP1879013A4 (en) * | 2005-04-20 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS |
BRPI0613005A8 (pt) * | 2005-07-15 | 2017-12-26 | Angiochem Inc | uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos. |
EP1762232A1 (en) | 2005-09-09 | 2007-03-14 | Warner-Lambert Company LLC | Liquid filled delivery system, preferably an HPMC capsule filled with glycerol |
AR066076A1 (es) * | 2007-04-18 | 2009-07-22 | Sandoz Ag | Procedimiento para dosificar sistemas de liberacion de farmacos auto-emulsionantes |
MX2009013663A (es) * | 2007-06-22 | 2010-01-27 | Scidose Llc | Formulacion solubilizada de docetaxel sin tween 80. |
WO2009063367A1 (en) * | 2007-11-15 | 2009-05-22 | Pfizer Products Inc. | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
US9180088B2 (en) | 2008-03-07 | 2015-11-10 | Scidose, Llc | Fulvestrant formulations |
BRPI0909187A2 (pt) | 2008-03-20 | 2015-08-04 | Virun Inc | Emulsões incluindo tocoferol de derivados de peg |
US8765661B2 (en) | 2008-03-20 | 2014-07-01 | Virun, Inc. | Compositions containing non-polar compounds |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
CA2766799A1 (en) * | 2009-06-26 | 2010-12-29 | Eric Kuhrts | Water-soluble dietary fatty acids |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
CA2690490C (en) * | 2010-01-19 | 2012-06-26 | Accucaps Industries Limited | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
WO2011119228A1 (en) | 2010-03-23 | 2011-09-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
US10286056B2 (en) * | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
SG11201404640YA (en) | 2012-02-10 | 2014-09-26 | Virun Inc | Beverage compositions containing non-polar compounds |
US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
JP6464084B2 (ja) * | 2012-07-27 | 2019-02-06 | イズミ テクノロジー,エルエルシー | 排出阻害剤およびこれを用いる治療法 |
US9744210B2 (en) | 2012-12-27 | 2017-08-29 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with P-glycoprotein inhibitors |
CN105120842B (zh) * | 2013-02-28 | 2020-12-01 | 普罗诺瓦生物医药挪威公司 | 包含脂质化合物、甘油三酯和表面活性剂的组合物以及使用它们的方法 |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
EP3065718A4 (en) | 2013-10-06 | 2017-07-12 | Sarfez Pharmaceuticals, Inc. | Controlled-release formulations comprising torsemide |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
EP3881829A1 (en) * | 2014-11-07 | 2021-09-22 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
TWI715636B (zh) | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
WO2017085687A1 (en) | 2015-11-20 | 2017-05-26 | West-Ward Pharmaceuticals International Limited | Stable formulation of phenobarbital sodium injection |
WO2017123933A1 (en) | 2016-01-15 | 2017-07-20 | Massachusetts Eye And Ear Infirmary | Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis |
US11911413B2 (en) | 2018-02-16 | 2024-02-27 | Proteobioactives Pty Limited | Methods and compositions for the treatment of pain and/or inflammation |
MX2018013458A (es) * | 2018-11-05 | 2019-07-25 | Federico Amezcua Amezcua | Composicion farmaceutica que comprende la combinacion de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamacion y contractura muscular. |
WO2023220109A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU510985B2 (en) | 1977-03-29 | 1980-07-24 | Capsugel A.G. | Liquid filled capsule |
US4498421A (en) | 1982-07-19 | 1985-02-12 | Michael Douglas Fredrick | Self-cleaning cage |
EP0211079A4 (en) | 1985-01-31 | 1988-02-15 | Fujisawa Pharmaceutical Co | BENDABLE CAPSULE WITH SEVERAL CHAMBERS, METHOD AND DEVICE FOR THEIR PRODUCTION. |
US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US5616458A (en) * | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
US5264223A (en) | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
EP0706373B1 (en) | 1992-03-23 | 2000-07-19 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5442252A (en) | 1992-11-16 | 1995-08-15 | General Electric Company | Lenticulated lens with improved light distribution |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6491938B2 (en) * | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
US5475018A (en) * | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
DK0924201T3 (da) * | 1993-11-30 | 2002-05-21 | Searle & Co | Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
AU2424895A (en) * | 1994-05-04 | 1995-11-29 | G.D. Searle & Co. | Substituted spirodienes for the treatment of inflammation |
US5418254A (en) * | 1994-05-04 | 1995-05-23 | G. D. Searle & Co. | Substituted cyclopentadienyl compounds for the treatment of inflammation |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
CA2195847A1 (en) * | 1994-07-27 | 1996-02-08 | John J. Talley | Substituted thiazoles for the treatment of inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
GB9416902D0 (en) | 1994-08-20 | 1994-10-12 | Scherer Corp R P | Hydrophilic controlled release device |
DE4447770C2 (de) | 1994-08-20 | 2002-12-19 | Max Delbrueck Centrum | Verfahren zur Herstellung von liposomal verkapseltem Taxol |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5585504A (en) * | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
US5696143A (en) * | 1994-09-20 | 1997-12-09 | Talley; John J. | Benz G! indazolyl derivatives for the treatment of inflammation |
US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
CA2200462A1 (en) * | 1994-10-27 | 1996-05-09 | Merck Frosst Canada Inc. | Stilbene derivatives useful as cyclooxygenase-2 inhibitors |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
JP2636819B2 (ja) * | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
US5552422A (en) * | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
WO1996023786A1 (en) * | 1995-01-31 | 1996-08-08 | Merck Frosst Canada Inc. | 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2 |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
AU708964B2 (en) * | 1995-05-25 | 1999-08-19 | G.D. Searle & Co. | Method of preparing 3-haloalkyl-1h-pyrazoles |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9514518D0 (en) * | 1995-07-15 | 1995-09-13 | Sod Conseils Rech Applic | Guanidine salt inhibitors of NO synthase and cyclooxygenase |
JPH0977664A (ja) * | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−2特異的阻害剤及び抗炎症剤 |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6964946B1 (en) | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US5968972A (en) | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
US6057319A (en) * | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
CZ216498A3 (cs) * | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corporation | Nové substituované imidazolové sloučeniny |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
US5789413A (en) * | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
US5733909A (en) * | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
ES2202492T3 (es) | 1996-03-25 | 2004-04-01 | Synthes Ag Chur | Pinza regulable para elementos de fijacion para huesos. |
GB9607503D0 (en) * | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5807873A (en) * | 1996-04-04 | 1998-09-15 | Laboratories Upsa | Diarylmethylidenefuran derivatives and their uses in therapeutics |
PL195955B1 (pl) * | 1996-04-12 | 2007-11-30 | Searle & Co | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie |
US5922742A (en) * | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
BR9709097A (pt) * | 1996-05-17 | 1999-08-03 | Merck & Co Inc | Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária |
US5883267A (en) * | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
WO1997046532A1 (en) * | 1996-06-03 | 1997-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-benzyl-4-sulfonyl-4h-isoquinolin-1,3-diones and their use as anti-inflammatory agents |
US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
US5776967A (en) * | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
FR2751964B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique |
KR20000029784A (ko) * | 1996-08-02 | 2000-05-25 | 나까도미 히로다카 | 경구제제용캡슐과경구캡슐제제 |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
US6005000A (en) * | 1996-08-22 | 1999-12-21 | Oxis International, Inc. | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor |
FR2753449B1 (fr) * | 1996-09-13 | 1998-12-04 | Union Pharma Scient Appl | Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique |
EP0868422A1 (de) | 1996-09-24 | 1998-10-07 | Marigen S.A. | Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral und antiviral wirksamen estern von baccatin-iii-verbindungen |
US5972950A (en) * | 1996-10-08 | 1999-10-26 | Laboratories Upsa | 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics |
US5681842A (en) * | 1996-11-08 | 1997-10-28 | Abbott Laboratories | Prostaglandin synthase-2 inhibitors |
US5869524A (en) * | 1996-11-12 | 1999-02-09 | American Home Products Corporation | Indene inhibitors of COX-2 |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5935990A (en) * | 1996-12-10 | 1999-08-10 | G.D. Searle & Co. | Substituted pyrrolyl compounds for the treatment of inflammation |
US5973191A (en) * | 1996-12-30 | 1999-10-26 | Vanderbilt University | Selective inhibitors of prostaglandin endoperoxide synthase-2 |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US5929076A (en) * | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
US6071954A (en) * | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
CH688504A5 (de) | 1997-03-26 | 1997-10-31 | Marigen Sa | Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamem Taxol und mit Taxol-analogen Verbindungen. |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
JP2002500667A (ja) | 1997-05-27 | 2002-01-08 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 |
WO1998058927A1 (en) | 1997-06-20 | 1998-12-30 | Baker Norton Pharmaceuticals, Inc. | Soluble prodrugs of paclitaxel |
EP0999826B1 (en) | 1997-07-29 | 2004-05-06 | PHARMACIA & UPJOHN COMPANY | Self-emulsifying formulation for lipophilic compounds |
US6046217A (en) * | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
US6040450A (en) * | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
FR2769311B1 (fr) * | 1997-10-07 | 1999-12-24 | Union Pharma Scient Appl | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
FR2771412B1 (fr) * | 1997-11-26 | 2000-04-28 | Adir | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6887893B1 (en) * | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
IL131217A0 (en) | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
IL139127A0 (en) * | 1998-04-24 | 2001-11-25 | Merck & Co Inc | Process for synthesizing cox -2 inhibitors |
WO1999059583A1 (en) * | 1998-05-18 | 1999-11-25 | Merck & Co., Inc. | Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia |
AU757343B2 (en) | 1998-09-28 | 2003-02-20 | Capsugel Belgium Nv | Enteric and colonic delivery using HPMC capsules |
US6077869A (en) * | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
WO2000027367A1 (en) | 1998-11-11 | 2000-05-18 | Bioprogress Technology International Incorporated | A capsule based drug delivery system |
AU2024900A (en) | 1998-11-16 | 2000-06-05 | A.B.Technologies, L.L.C. | Multi chamber soft capsules and method of making the same |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
WO2000033862A1 (en) | 1998-12-11 | 2000-06-15 | Pharmasolutions, Inc. | Self-emulsifying compositions for drugs poorly soluble in water |
JP2000237284A (ja) | 1999-02-17 | 2000-09-05 | Shionogi Qualicaps Kk | 硬質カプセル製剤 |
US6610317B2 (en) * | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
KR100752000B1 (ko) | 1999-05-27 | 2007-08-28 | 아쿠스피어 인코포레이티드. | 다공성 약물 매트릭스의 제조방법 |
GB9916033D0 (en) | 1999-07-09 | 1999-09-08 | Bioprogress Tech Int Inc | A multiple delivery capsule |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
US6083969A (en) * | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
AU2001251650A1 (en) * | 2000-04-18 | 2001-10-30 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 |
MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
JP2004503588A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−2阻害薬および血管調節化合物 |
WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
-
2002
- 2002-01-14 US US10/047,902 patent/US7115565B2/en not_active Expired - Fee Related
- 2002-01-15 CA CA002434338A patent/CA2434338A1/en not_active Abandoned
- 2002-01-15 NZ NZ526976A patent/NZ526976A/en unknown
- 2002-01-15 KR KR10-2003-7009549A patent/KR20030070118A/ko not_active Application Discontinuation
- 2002-01-15 EP EP02709027A patent/EP1365812A2/en not_active Withdrawn
- 2002-01-15 US US10/047,222 patent/US20030045563A1/en not_active Abandoned
- 2002-01-15 PE PE2002000019A patent/PE20020799A1/es not_active Application Discontinuation
- 2002-01-15 PL PL02363215A patent/PL363215A1/xx not_active Application Discontinuation
- 2002-01-15 EA EA200300752A patent/EA006383B1/ru not_active IP Right Cessation
- 2002-01-15 MX MXPA03006357A patent/MXPA03006357A/es not_active Application Discontinuation
- 2002-01-15 BR BR0206580-0A patent/BR0206580A/pt not_active IP Right Cessation
- 2002-01-15 WO PCT/US2002/000971 patent/WO2002056878A2/en active IP Right Grant
- 2002-01-15 CZ CZ20031844A patent/CZ20031844A3/cs unknown
- 2002-01-15 JP JP2002557386A patent/JP2004520359A/ja not_active Withdrawn
- 2002-01-15 IL IL15691602A patent/IL156916A0/xx unknown
- 2002-01-15 CN CNB028067665A patent/CN100335136C/zh not_active Expired - Fee Related
- 2002-01-18 AR ARP020100196A patent/AR035735A1/es unknown
-
2003
- 2003-07-17 NO NO20033244A patent/NO20033244L/no not_active Application Discontinuation
-
2004
- 2004-11-12 HK HK04108957A patent/HK1065959A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20033244L (no) | 2003-09-17 |
NO20033244D0 (no) | 2003-07-17 |
WO2002056878A2 (en) | 2002-07-25 |
EA200300752A1 (ru) | 2004-02-26 |
PL363215A1 (en) | 2004-11-15 |
US7115565B2 (en) | 2006-10-03 |
NZ526976A (en) | 2005-02-25 |
MXPA03006357A (es) | 2003-10-06 |
IL156916A0 (en) | 2004-02-08 |
WO2002056878A3 (en) | 2002-12-19 |
CZ20031844A3 (cs) | 2003-12-17 |
US20030045563A1 (en) | 2003-03-06 |
KR20030070118A (ko) | 2003-08-27 |
BR0206580A (pt) | 2003-12-16 |
EP1365812A2 (en) | 2003-12-03 |
US20020156124A1 (en) | 2002-10-24 |
HK1065959A1 (en) | 2005-03-11 |
PE20020799A1 (es) | 2002-09-11 |
JP2004520359A (ja) | 2004-07-08 |
CN1498114A (zh) | 2004-05-19 |
CA2434338A1 (en) | 2002-07-25 |
EA006383B1 (ru) | 2005-12-29 |
CN100335136C (zh) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035735A1 (es) | Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamento | |
JP6913795B2 (ja) | ロキソプロフェンを含有する医薬組成物5 | |
DE69837474T2 (de) | Antimikrobielle vorbeugung gegen und behandlung von aids und anderer infektiöser krankheiten | |
JP6764913B2 (ja) | ロキソプロフェンを含有する医薬組成物<参> | |
JP5073651B2 (ja) | 抗ウィルス剤、抗腫瘍剤または抗寄生虫剤ならびにカルベオール、チモール、オイゲノール、ボルネオールおよびカルバクロールから選択される活性剤を含んでなる製薬組成物 | |
CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
BRPI0518266A2 (pt) | medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular | |
WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
DE602006016146D1 (de) | Glycyrrhetinsäure-30-amidderivate und anwendungen davon | |
PA8542701A1 (es) | Composición parenteral reconstituible | |
YU2703A (sh) | Bistar vodeni anestetski preparat | |
CN115884761A (zh) | 大麻素的透皮药物制剂 | |
US20160151436A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
RU2009103908A (ru) | Композиция для лечения хронических дегенеративных воспалительных заболеваний | |
EA200501621A1 (ru) | Антигриппозное средство | |
Aljeboory et al. | Loranthus europaeus is an alternative medicine in treatment of cyst and mouth inflammation resulted from chemotherapy of breast cancer | |
BRPI0621416A2 (pt) | composição para o tratamento de doenças bacterianas, virais, fúngicas, inflamação e dor | |
DE50006842D1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung | |
BR0115506A (pt) | Composições farmacêuticas tendo uma ação antidiabética, e processo para sua preparação | |
WO2023016495A1 (zh) | 含有白果内酯和大麻二酚的药物组合物及其在医药上的应用 | |
JPH01163120A (ja) | 抗レトロウイルス剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |